Medtronic plcMDT
Medtronic plc Financial Overview 2021–2025
Medtronic is aggressively reshaping its portfolio to break free from stagnation, recently delivering 7% revenue growth in Q2 FY2026 alongside a 12% surge in its soon-to-be-separated Diabetes unit. This performance marks a clear shift from the modest single-digit gains of previous years, validating a thesis built on shedding lower-margin assets to unlock shareholder value. The company has successfully scaled its top line despite supply chain disruptions, growing revenue from $30.1 billion in FY2021 to $33.5 billion in FY2025.
Underlying this growth is a resurgence in core medical technologies, with the massive Cardiovascular segment expanding 11% in the most recent quarter driven by TAVR and cardiac rhythm adoption. Financial discipline remains central to the strategy, evidenced by $5.2 billion in free cash flow generated in FY2025 and $3.2 billion allocated to share repurchases during the same period. Even while absorbing a projected $185 million tariff impact for FY2026, the company maintained robust liquidity with $1.04 billion in free cash flow over the first half of the fiscal year. At the close of FY2025, the market valued this recovery at $84.16 per share, implying a 23.3x earnings multiple and a $107.9 billion market capitalization.
Recent Developments (Q1 and Q2 2026)
Medtronic prioritized profitability and balance sheet optimization through the first half of FY2026. While top-line momentum stabilized, bottom-line performance improved markedly, with Q2 2026 diluted EPS rising to $1.07 from $0.99 in the prior-year period. Across the first six months, the company generated $17.54 billion in revenue, an 8% year-over-year increase, supporting cumulative diluted EPS of $1.87. On the capital allocation front, management executed a €1.5 billion debt offering in September 2025, utilizing proceeds to refinance maturing obligations and extend the company's debt maturity profile without impacting liquidity.
The bull case rests on consistent operational execution and margin expansion, while the bear case cautions that the recent rally has stretched valuation metrics significantly. As of the November 24, 2025 report, shares closed at $105.35, reflecting a rich 29.2x P/E ratio that represents a premium compared to the company's historical trading range.
What to watch: Operational continuity following the EVP of Enterprise Operations retirement in December 2025; regulatory milestones for the Diabetes unit separation.
Rev
$33.54B
FY2025
NI
$4.66B
FY2025
EPS
$3.63
FY2025
OCF
$7.04B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
Medtronic plc 8-K Report, Financial Results (Feb 17, 2026)
Medtronic plc (MDT) has filed an 8-K report on February 17, 2026, to announce its third quarter fiscal year 2026 financial results. The primary purpose of this filing is to furnish the press release detailing these results, which were released on the same day. Investors should review the press release (Exhibit 99.1) for specific performance metrics, revenue figures, profitability, and any forward-looking statements or guidance provided by the company for the remainder of the fiscal year. This report serves as the official notification of the company's recent financial performance. While the 8-K itself is brief, it directs investors to the comprehensive financial data contained within the furnished press release. Key areas of interest for investors will likely include the performance of Medtronic's various business segments, comparisons to analyst expectations, and any commentary on the macroeconomic or industry-specific factors impacting the results. Understanding these details is crucial for assessing Medtronic's current financial health and future prospects.
Medtronic plc 8-K Report, Financial Results (Nov 18, 2025)
Medtronic plc (MDT) has filed a Form 8-K on November 18, 2025, to report its second quarter fiscal year 2026 financial results. The filing primarily consists of a press release containing these results, which is furnished as an exhibit. Investors should refer to the accompanying press release (Exhibit 99.1) for the detailed financial performance and operational highlights for the quarter ended November 17, 2025. While the 8-K itself does not provide the specific financial figures, it serves as the official notification of the release of this important information. Key metrics such as revenue, earnings per share (EPS), and segment performance, along with management's commentary on business outlook and strategic progress, will be found within the press release. Investors are encouraged to review this document thoroughly to understand Medtronic's current financial health and future prospects.
Medtronic plc 8-K Report, Executive Changes (Nov 3, 2025)
Medtronic plc announced on November 2, 2025, that its Executive Vice President, Enterprise Operations, Gregory L. Smith, will retire from the company effective December 2, 2025. Mr. Smith's departure marks a leadership transition within the company's operations segment. Investors should note that his retirement triggers specific provisions regarding his outstanding equity compensation, as detailed in the company's filings.
Medtronic plc 8-K Report, Bylaw Amendment (Oct 21, 2025)
Medtronic plc (MDT) filed an 8-K detailing the outcomes of its Annual General Meeting held on October 16, 2025. The primary focus of this report is the shareholder approval of significant amendments to the company's Articles of Association. These amendments, effective October 16, 2025, include modifications to Article 177 to enable the Board of Directors to capitalize non-distributable reserves for the creation of additional distributable reserves, and updates to the company's advance notice provisions for shareholder proposals. Beyond the governance-related changes, the meeting also saw shareholders overwhelmingly re-elect all twelve director nominees. Furthermore, investors ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026 and approved the compensation of named executive officers in advisory votes. The company also secured shareholder approval for renewing the Board's authority to issue shares and opt out of pre-emption rights, along with authorizing overseas market purchases of Medtronic ordinary shares. A capital reduction to create distributable reserves under Irish Law was also approved.
Medtronic plc 8-K Report, Material Agreement (Sep 29, 2025)
Medtronic plc (MDT) has filed an 8-K report detailing a significant debt offering and the redemption of existing notes. On September 29, 2025, an indirect wholly owned subsidiary, Medtronic, Inc., successfully issued €1.5 billion in aggregate principal amount of senior notes, split between 2.950% Senior Notes due 2030 and 4.200% Senior Notes due 2045. These new notes are fully and unconditionally guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc. The primary purpose of this offering is to refinance existing debt. Medtronic, Inc. expects to use the net proceeds of approximately €1.49 billion to repay Medtronic Luxco's 0.000% Senior Notes due 2025 and its 2.625% Senior Notes due 2025. Concurrently, Medtronic Luxco has redeemed all outstanding €500 million of its 2.625% Senior Notes due 2025, with this redemption being contingent on the successful completion of the new notes issuance. This strategic debt management indicates Medtronic's effort to optimize its capital structure and extend its debt maturity profile.
View all 8-K filings →